Catherine C Coombs
Overview
Explore the profile of Catherine C Coombs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
1793
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Danilov A, Sauter C, Phillips T, Coombs C, Ip A, Wang Y, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 39919997
Recent years have brought a much-needed paradigm shift to the management and treatment of mature B-cell lymphomas. Pathophysiologic and clinical heterogeneity within the various subtypes have historically contributed to treatment...
2.
Ghosh N, Eyre T, Brown J, Lamanna N, Manzoor B, Coombs C, et al.
Am J Hematol
. 2024 Dec;
100(3):511-515.
PMID: 39698781
No abstract available.
3.
Lee J, Beers J, Cheng I, Truong V, Brown Z, Muluneh B, et al.
Clin Transl Sci
. 2024 Dec;
17(12):e70106.
PMID: 39673246
Venetoclax is a first-in-class orally administered B-cell lymphoma-2 inhibitor used to treat chronic lymphocytic leukemia (CLL). Venetoclax is primarily metabolized in the liver by cytochrome P450 (CYP) 3A4 to its...
4.
Soumerai J, Barrientos J, Barrientos J, Ahn I, Ahn I, Coombs C, et al.
Blood Adv
. 2024 Nov;
9(5):1213-1229.
PMID: 39561376
Over the past decade, treatment recommendations for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have shifted from traditional chemoimmunotherapy to targeted therapies. Multiple new therapies are...
5.
Shah N, Wang M, Roeker L, Patel K, Woyach J, Wierda W, et al.
Haematologica
. 2024 Oct;
110(1):92-102.
PMID: 39363864
Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation. The phase I/II BRUIN study evaluated pirtobrutinib, a highly selective...
6.
Jensen J, Bobek O, Chan I, Miller B, Hillman D, Heller G, et al.
Clin Cancer Res
. 2024 Sep;
30(21):4910-4919.
PMID: 39287426
Purpose: Mutations in hematopoietic progenitor cells accumulate with age leading to clonal expansion, termed clonal hematopoiesis (CH). CH in the general population is associated with hematopoietic neoplasms and reduced overall...
7.
Gajagowni S, Hopkins S, Qadeer Y, Virani S, Verdonschot J, Coombs C, et al.
Prog Cardiovasc Dis
. 2024 Sep;
86:79-85.
PMID: 39278303
Clonal hematopoiesis of indeterminate potential (CHIP) is a well-studied phenomenon in hematologic malignancies. With advancements in gene sampling and analysis and the use of large cohort studies, CHIP has recently...
8.
Wierda W, Shah N, Cheah C, Lewis D, Hoffmann M, Coombs C, et al.
Lancet Haematol
. 2024 Jul;
11(9):e682-e692.
PMID: 39033770
Background: Richter transformation usually presents as an aggressive diffuse large B-cell lymphoma, occurs in up to 10% of patients with chronic lymphocytic leukaemia, has no approved therapies, and is associated...
9.
Xie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, et al.
Blood
. 2024 Jul;
144(19):2033-2044.
PMID: 38996210
Clonal cytopenia of undetermined significance (CCUS) represents a distinct disease entity characterized by myeloid-related somatic mutations with a variant allele fraction of ≥2% in individuals with unexplained cytopenia(s) but without...
10.
Roeker L, Woyach J, Cheah C, Coombs C, Shah N, Wierda W, et al.
Blood
. 2024 Jun;
144(13):1374-1386.
PMID: 38861666
Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). Patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) were treated with fixed-duration pirtobrutinib plus venetoclax (PV)...